JP2011516041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516041A5 JP2011516041A5 JP2010550830A JP2010550830A JP2011516041A5 JP 2011516041 A5 JP2011516041 A5 JP 2011516041A5 JP 2010550830 A JP2010550830 A JP 2010550830A JP 2010550830 A JP2010550830 A JP 2010550830A JP 2011516041 A5 JP2011516041 A5 JP 2011516041A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antibodies
- seq
- tyrp1
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6919908P | 2008-03-12 | 2008-03-12 | |
| US61/069,199 | 2008-03-12 | ||
| PCT/US2009/036739 WO2009114585A1 (en) | 2008-03-12 | 2009-03-11 | Anti-tyrp1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011516041A JP2011516041A (ja) | 2011-05-26 |
| JP2011516041A5 true JP2011516041A5 (https=) | 2014-03-06 |
Family
ID=40790741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550830A Pending JP2011516041A (ja) | 2008-03-12 | 2009-03-11 | 抗ｔｙｒｐ１抗体 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7951370B2 (https=) |
| EP (1) | EP2268672A1 (https=) |
| JP (1) | JP2011516041A (https=) |
| KR (1) | KR101203777B1 (https=) |
| CN (1) | CN101970500B (https=) |
| AR (1) | AR070821A1 (https=) |
| AU (1) | AU2009222998B2 (https=) |
| BR (1) | BRPI0909633A2 (https=) |
| CA (1) | CA2718289A1 (https=) |
| CL (1) | CL2009000567A1 (https=) |
| EA (1) | EA019517B1 (https=) |
| IL (1) | IL207581A0 (https=) |
| MX (1) | MX2010010021A (https=) |
| NZ (1) | NZ587305A (https=) |
| PE (1) | PE20091679A1 (https=) |
| TW (1) | TWI384997B (https=) |
| UA (1) | UA99339C2 (https=) |
| WO (1) | WO2009114585A1 (https=) |
| ZA (1) | ZA201006099B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2167540T (lt) * | 2007-06-29 | 2018-04-25 | F. Hoffmann-La Roche Ag | Sunkioji grandinė mutantė, pagerinanti imunoglobulino gamybą |
| SG11201606439VA (en) | 2014-02-07 | 2016-09-29 | Dong Wha Pharm Co Ltd | Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug |
| DK3233907T3 (da) | 2014-12-19 | 2021-06-07 | Genmab As | Bispecifikke heterodimeriske proteiner hos gnavere |
| RU2630647C1 (ru) * | 2016-05-27 | 2017-09-11 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА |
| GB201613167D0 (en) | 2016-07-29 | 2016-09-14 | Univ Southampton | Cancer and b-cell related disease therapy |
| WO2018075586A1 (en) * | 2016-10-18 | 2018-04-26 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof |
| AU2017418590A1 (en) * | 2017-06-14 | 2020-01-16 | Adicet Therapeutics, Inc. | Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof |
| RU2687609C1 (ru) * | 2018-05-30 | 2019-05-15 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека |
| PL3856775T3 (pl) | 2018-09-27 | 2025-06-09 | Autolus Limited | Chimeryczny receptor antygenowy |
| US12371507B2 (en) | 2018-11-09 | 2025-07-29 | Beth Israel Deaconess Medical Center | CDCP1 antibodies and antibody drug conjugates |
| SG10202105788SA (en) * | 2018-12-21 | 2021-06-29 | Hoffmann La Roche | Antibodies binding to cd3 |
| AU2020343025A1 (en) * | 2019-09-06 | 2022-04-07 | The Regents Of The University Of California | Chimeric antigen receptors and related methods and compositions for the treatment of cancer |
| CN115515976A (zh) * | 2020-03-19 | 2022-12-23 | 帝国理工学院创新有限公司 | 冠状病毒抗体 |
| JP2024543257A (ja) * | 2021-11-26 | 2024-11-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｔｙｒｐ１／抗ｃｄ３二重特異性抗体およびｔｙｒｐ１特異性抗体の併用療法 |
| WO2025104289A1 (en) | 2023-11-17 | 2025-05-22 | Medincell S.A. | Antineoplastic combinations |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4798790A (en) * | 1985-07-18 | 1989-01-17 | Sloan-Kettering Institute | Monoclonal antibody specific for a pigmentation associated antigen |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| ES2070172T3 (es) | 1988-04-16 | 1995-06-01 | Celltech Ltd | Procedimiento para producir proteinas mediante adn recombinante. |
| IE910820A1 (en) | 1990-03-22 | 1991-09-25 | Sloan Kettering Inst Cancer | Gp75 as a tumor vaccine for melanoma |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
| AU6171196A (en) | 1995-06-07 | 1996-12-30 | Sloan-Kettering Institute For Cancer Research | Therapeutic uses of ta99 |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| BR9815289A (pt) * | 1997-11-14 | 2001-12-26 | Euro Celtique Sa | Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado |
| IL152804A0 (en) * | 2000-05-16 | 2003-06-24 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| JP5553963B2 (ja) * | 2004-10-22 | 2014-07-23 | アムジエン・インコーポレーテツド | 組換え抗体をリフォールディングする方法 |
-
2009
- 2009-03-11 AU AU2009222998A patent/AU2009222998B2/en not_active Ceased
- 2009-03-11 CA CA2718289A patent/CA2718289A1/en not_active Abandoned
- 2009-03-11 KR KR1020107020296A patent/KR101203777B1/ko not_active Expired - Fee Related
- 2009-03-11 MX MX2010010021A patent/MX2010010021A/es active IP Right Grant
- 2009-03-11 EP EP09719438A patent/EP2268672A1/en not_active Withdrawn
- 2009-03-11 CN CN2009801085150A patent/CN101970500B/zh not_active Expired - Fee Related
- 2009-03-11 UA UAA201010912A patent/UA99339C2/ru unknown
- 2009-03-11 TW TW098107909A patent/TWI384997B/zh not_active IP Right Cessation
- 2009-03-11 EA EA201071068A patent/EA019517B1/ru not_active IP Right Cessation
- 2009-03-11 NZ NZ587305A patent/NZ587305A/en not_active IP Right Cessation
- 2009-03-11 JP JP2010550830A patent/JP2011516041A/ja active Pending
- 2009-03-11 BR BRPI0909633A patent/BRPI0909633A2/pt not_active IP Right Cessation
- 2009-03-11 US US12/401,800 patent/US7951370B2/en not_active Expired - Fee Related
- 2009-03-11 AR ARP090100858A patent/AR070821A1/es not_active Application Discontinuation
- 2009-03-11 PE PE2009000356A patent/PE20091679A1/es not_active Application Discontinuation
- 2009-03-11 CL CL2009000567A patent/CL2009000567A1/es unknown
- 2009-03-11 WO PCT/US2009/036739 patent/WO2009114585A1/en not_active Ceased
-
2010
- 2010-08-12 IL IL207581A patent/IL207581A0/en unknown
- 2010-08-26 ZA ZA2010/06099A patent/ZA201006099B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011516041A5 (https=) | ||
| EP3683239B1 (en) | Antibodies binding human claudin 18.2 and uses thereof | |
| TWI384997B (zh) | 抗酪胺酸酶相關蛋白-１（ｔｙｒｐ１）抗體 | |
| JP7575102B2 (ja) | Ｍｕｃ１８に特異的な抗体 | |
| CN105968206B (zh) | 抗erbb3抗体 | |
| JP2021531826A (ja) | 栄養膜細胞表面抗原２（ｔｒｏｐ２）に対する特異的な抗体 | |
| EP4166196A1 (en) | Antibodies binding cd24, preparation and use thereof | |
| CN108290948A (zh) | 抗-cd47抗体及使用方法 | |
| EP4292611A1 (en) | Anti-cd112r antibody and use thereof | |
| US20100092455A1 (en) | Novel anti-proliferation antibodies | |
| CN113474362A (zh) | 对cd44特异性的抗体 | |
| RU2754760C2 (ru) | Водная фармацевтическая композиция анти-il17a антитела и ее применение | |
| JP7578289B2 (ja) | Ｍｕｃ１８に特異的な抗体 | |
| KR102500845B1 (ko) | 항-tigit 항체 및 이의 용도 | |
| WO2020098672A1 (zh) | 一种融合蛋白及其用途 | |
| CN116262790A (zh) | 嵌合的抗cd27抗体组合物及其应用 | |
| WO2023093831A1 (zh) | 包含SIRPα突变体的融合蛋白 | |
| WO2023045859A1 (zh) | Cd38单克隆抗体及其应用 | |
| CN119584995A (zh) | 组合疗法 | |
| EP4549466A1 (en) | Development and use of novel multispecific tumor inhibitor | |
| HK40120136A (zh) | 针对警报素的双特异性结合蛋白及其用途 | |
| WO2025182946A1 (ja) | 肥満細胞が病態を増悪させる疾患の治療及び／又は予防用医薬組成物 | |
| KR20260013464A (ko) | 항-콜로니 자극 인자 1 수용체 항체를 이용한 만성 이식편대숙주 질환-관련 폐쇄성 세기관지염 증후군의 치료 방법 | |
| NZ791361B2 (en) | Engineered anti-il-2 antibodies | |
| HK40029982B (en) | Antibodies binding human claudin 18.2 and uses thereof |